#United States #New Orleans #Artivion #NEXUS TRIOMPHE #Aortic Disease

Artivion Presents Groundbreaking Clinical Findings

Artivion, Inc., a notable player in the field of cardiac and vascular surgery, particularly in aortic diseases, made waves at the 62nd Annual Meeting of the Society of Thoracic Surgeons held in New Orleans, Louisiana. During the event, they presented pivotal new clinical data derived from two significant trials: the NEXUS TRIOMPHE and AMDS PERSEVERE trials. Both trials have led to noteworthy advancements in the treatment of aortic conditions.

Highlights from the NEXUS TRIOMPHE Trial

The NEXUS TRIOMPHE IDE trial focused on patients dealing with chronic aortic dissection, aneurysm, and other arch diseases. The study included 94 high-risk patients who underwent treatment with the NEXUS device. The results were astonishing:

• - 94% patient survival from complications related to lesions after one year.
• - 91% freedom from disabling stroke, showcasing the efficacy of the treatment in preventing such serious outcomes.
• - An impressive 97% of patients were free from reintervention due to endoleaks, with no renal failure incidents reported.
• - Minimal side effects reported, with only one occurrence of paraplegia noted.

Pat Mackin, the Chairman, President, and CEO of Artivion, expressed satisfaction with these promising outcomes, emphasizing their importance for patients suffering from aortic arch disease. The success of this trial marks a substantial forward step in the medical community's approach to treating aortic conditions.

Dr. Himanshu Patel, a prominent figure in cardiac surgery, presented the findings and remarked on the potential the NEXUS device holds for providing effective treatment options for high-risk patients, indicating a bright future for aortic arch interventions.

Insights from the AMDS PERSEVERE Trial

The AMDS PERSEVERE IDE trial, on the other hand, focused on a novel hybrid prosthesis aimed at treating acute DeBakey Type I dissection. This trial also delivered remarkable findings:

• - Minimal additional mortality, with funding only 4 deaths due to unrelated causes.
• - Consistent results in the rates of unanticipated aortic reoperations, maintaining a low statistic of 4.3%.
• - No signs of new entry tears were reported, indicating the effectiveness of the AMDS solution.
• - Stable total aortic diameter across various zones, demonstrating a mean change of less than 2mm, while also seeing a mean true lumen diameter expansion of up to 1.7mm.

Dr. Kyle Eudailey, involved with the University of Alabama at Birmingham, presented this data and highlighted the significance of these results, confirming that the AMDS approach is vital in effectively managing acute aortic dissections.

About Artivion, Inc.

Founded and based in suburban Atlanta, Georgia, Artivion, Inc. has carved out a niche for itself in the medical device industry by focusing on creating innovative solutions that tackle some of the most challenging problems faced by cardiac and vascular surgeons dealing with aortic diseases. The company boasts a diverse product lineup, including aortic stent grafts, surgical sealants, and mechanical heart valves, which are available in more than 100 countries.

As Artivion continues to lead in medical advancements within the realm of aortic disease treatment, these recent study results serve as a testament to the potential for improved patient outcomes and quality of life, paving the way for future innovations.

For more details about Artivion's initiatives, visit their official website: www.Artivion.com.